Landmarks in non-hormonal pharmacological therapies for castration-resistant prostate cancer
Article first published online: 10 OCT 2012
© 2012 THE AUTHOR. BJU INTERNATIONAL © 2012 BJU INTERNATIONAL
Special Issue: Landmarks in Prostate Cancer
Volume 110, Issue Supplement s1, pages 14–22, October 2012
How to Cite
Clarke, N. W. (2012), Landmarks in non-hormonal pharmacological therapies for castration-resistant prostate cancer. BJU International, 110: 14–22. doi: 10.1111/j.1464-410X.2012.11430.x
- Issue published online: 10 OCT 2012
- Article first published online: 10 OCT 2012
- prostate cancer;
- castration-resistant prostate cancer
- • The treatment of metastatic and castration-resistant prostate cancer (CRPC) has advanced considerably from the era where it was considered that the disease was resistant to chemotherapy.
- • Cytotoxic chemotherapy involving docetaxel is now used routinely as a first-line therapy after failed first- and second-line androgen deprivation in advanced disease, improving quality of life and to a limited extent, survival in patients with advanced prostate cancer.
- • The cytotoxic taxane, cabazitaxel has also become a second-line treatment option for patients with CRPC failing previous docetaxel therapy.
- • Additionally, a broad range of agents are now available or under development including immune-based therapies (cellular therapies and vaccines), bone-targeting agents (anti-osteolytic and anti-tumour therapies) and molecular-based agents targeting cellular control mechanisms.
- • Most of these remain experimental but on-going pharmacological development will inevitably provide urologists and urological oncologists with a broader range of therapeutic options for better cancer management in the future.